Micro Market Research
+1-888-502-0539
US/CAN Toll Free

You are here :   Home     Healthcare     infertility Treatment     In Vitro Diagnostics    
Real Time Market Research & Industry Analysis - MicroMarketMonitor

Global Tissue Diagnostics Market Research Report

  • Report Code: TI 1000
  • Publish Date: Upcoming
  
Description
Table of Contents
Customer Intelligence
Summary
Inquiry Before Buying Ask for Discount

The Global Tissue Diagnostics Devices Market is driven by increasing incidence of cancer.The Tissue Diagnostics Devices market value was estimated to be $1,463.87 million in 2013 and is expected to be $2,069.02 million by 2018, at a CAGR of 7.10% from 2013 to 2018. The Immunohistochemistry is the largest segment of $1,463.80 million Tissue Diagnostics Device market.

 

The report “Tissue Diagnostics Devices Market Forecast, 2012-2018”, analyzes the market in terms of technology such as Immunohistochemistry (IHC), in situ hybridization (ISH), digital pathology, and special staining. The segmentation of the market in terms of different diseases that occur is breast cancer, gastric cancer, lymphoma, prostate cancer, non-small-cell lung cancer (NSCLC), and other disease segments. All the segments experienced a positive growth till 2012 with an increased awareness for procedures and sophisticated diagnostic techniques. With a market value of $0.9 and $0.4 billion, the segments of breast and gastric cancer have been contributing in terms of value towards total tissue diagnostics industry. Both the markets have been witnessing the maximum growth because of increase in patient pool and procedure numbers of breast and gastric cancer.

 

Procedure volume growth is significantly higher in BIC (Brazil, India, and China) and Mexico because of fast disease progression, higher prevalence, improving healthcare infrastructure, economic growth, broadening insurance coverage, expanding private healthcare sector, and increasing awareness amongst people. In North America (US, Canada) and Europe (Germany, France, Italy, Spain, UK), the rising rates of cancer population have been driving the procedure growth

 

According to the International Agency for Research on Cancer (IARC) and World Health Organization (WHO), the number of new cancer cases detected every year is expected to rise from 14.1 million from 2012 to 19.3 million by 2025.

 

The major factors influencing the global tissue diagnostics market are increased usage of personalized medicine for cancer, growth of the IVD market, rapidly aging population, and rising incidences of cancer

 

The report provides an extensive competitive landscaping of companies operating in the Tissue Diagnostics Devices market. The key players of  the Tissue Diagnostics market extensively covered in the report are Abbott Laboratories, Inc. (U.S.), Roche Diagnostics Limited (Switzerland), Danaher Corporation (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Life Technologies (U.S.), Sigma-Aldrich (U.S.), Agilent Technologies (U.S.), Biogenex Laboratories (U.S.), Cell Signaling Technology, Inc. (U.S.), and Bio SB (U.S.). The details of segment and country-specific company shares, news and deals, M&A, segment-specific pipeline products, product approvals and product recalls of the major companies is also covered in the report.

 

Customization Options

 

Along with the market data, you can also customize MMM assessments that meet your company’s specific needs. Customize to get comprehensive industry standard and deep-dive analysis of the following parameters:

 

Product Analysis

  • Usage pattern (in-depth trend analysis) of products (segment-wise)
  • Product matrix which gives a detailed comparison of product portfolio of each company mapped at country and sub-segment level
  • End-user adoption rate analysis of the products (segment and country wise)
  • Comprehensive coverage of product approvals, pipeline products, and product recalls

 

Epidemiology Data

  • Country-specific prevalence, incidence, patient pool, and mortality rate of breast cancer, gastric cancer, prostate and lung cancer
  • Disease progression (pattern analysis)

 

Procedure Volume Data

  • Number of  procedures performed annually in each country tracked till sub-segment level
  • Number of breast, prostate, gastric and lung cancer procedures performed in each country

 

Surgeons/Physicians Perception Analysis

  • Fast turn-around analysis of surgeons response to market events and trends
  • Pattern analysis of usage of Immunohistochemistry (IHC), in situ hybridization (ISH), digital pathology, and special staining by physicians
  • Surgeons opinion about products from different companies
  • Surgeons qualitative inputs on epidemiology data

 

Brand/Product Perception Matrix

  • Comprehensive study of customers perception and behavior through our inbuilt social connect tool checking the virality and tonality of blogs
  • Analysis of overall brand usage and familiarity and brand advocacy distribution (detractor/neutral/familiar)

   

Pricing Trends

  • Cost analysis of tissue diagnostics devices in major countries
  • Immunohistochemistry (IHC), in situ hybridization (ISH), digital pathology, and special staining procedural investment in major countries

  

Competitive Intelligence

  • The company share analysis of tissue diagnostics devices for the top players of the market in the region
  • The crucial developments and strategies of companies inculcating in their portfolio for tissue diagnostics devices


1 Introduction
1.1 Analyst Insights
1.2 Market Definitions
1.3 Market Segmentation & Aspects Covered
1.4 Research Methodology
 

2 Executive Summary
 

3 Market Overview
 

4 By Submarkets
4.1 Next Generation Sequencing (NGS)
4.2 NGS Platforms/Consumables/Services
4.3 Immunohistochemistry
 

5 By Applications
5.1 Infectious Diseases
5.2 Cancers
5.3 Cardiovascular diseases
5.4 Drug Testing
5.5 Auto-immune Diseases
5.6 Nephrological diseases
5.7 Diabetes mellitus
5.8 Other Applications

 

6 By Endusers
6.1 Hospitals
6.2 Medical & Diagnostic Laboratories
6.3 Patient Self Testing
6.4 Point of Care Testing
6.5 Academics
6.6 Other Endusers
 

7 By Geographies
7.1 North America
7.2 Europe (Excluding Russia)
7.3 Asia
7.4 Rest of World
 

8 By Companies
8.1 Siemens AG Healthcare
8.2 Johnson & Johnson
8.3 Abbott Laboratories
8.4 Thermo Fisher Scientific
8.5 Other Companies
8.6 F. Hoffmann-La Roche Ltd.
8.7 Danaher Corporation

Please fill in the form below to receive a free copy of the Summary of this Report
















Global Tissue Diagnostics Market Research Report

* Enter the text from the image to the text box :

refresh captcha
Custom Market Research Services
We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Please visit http://www.micromarketmonitor.com/custom-research-services.html to specify your custom Research Requirement
PRODUCT TITLE PUBLISHED
Immunohistochemistry Immunohistochemistry
Immunohistochemistry and Next Generation Sequencing (NGS) and
Upcoming
North American Tissue Diagnostics North American Tissue Diagnostics
  The North American Tissue Diagnosis Devices Market, mainly driven by rapidly increasing incidence of cancer, value was estimated to be $1,228.14 million in 2013 and is expected to be $1,684.24 million by 2018, at a CAGR of 6.52% from 2013 to 2018. The market divided by 4 segments such as Immunohistochemistry (IHC), in situ hybridization (ISH), digital pathology, and special staining are the technology segments of the tissue diagnostics market. The major players are Abbott Laboratories, Inc. (U.S.), Roche Diagnostics Limited (Switzerland), Danaher Corporation (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Life Technologies (U.S.), Sigma-Aldrich (U.S.), Agilent Technologies (U.S.), Biogenex Laboratories (U.S.), Cell Signaling Technology, Inc. (U.S.), and Bio SB (U.S.).
Upcoming
European Tissue Diagnostics Market European Tissue Diagnostics Market
The European Tissue Diagnosis Devices Market, mainly driven by rapidly increasing incidence of cancer, which was valued $868.49 million in 2013 and is expected to be $1136.70 million by 2018, at a CAGR of 5.53% from 2013 to 2018. The market divided by 4 segments such as Immunohistochemistry (IHC), in situ hybridization (ISH), digital pathology, and special staining are the technology segments of the tissue diagnostics market. The major players are Abbott Laboratories, Inc. (U.S.), Roche Diagnostics Limited (Switzerland), Danaher Corporation (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Life Technologies (U.S.), Sigma-Aldrich (U.S.), Agilent Technologies (U.S.), Biogenex Laboratories (U.S.), Cell Signaling Technology, Inc. (U.S.), and Bio SB (U.S.).
Upcoming
BRIC Tissue Diagnostics BRIC Tissue Diagnostics
The BRIC Tissue Diagnosis Devices Market, mainly driven by rapidly increasing incidence of cancer, which was valued $264.75 million in 2013 and is expected to be $476.88 million by 2018, at a CAGR of 12.49% from 2013 to 2018. The market divided by 4 segments such as Immunohistochemistry (IHC), in situ hybridization (ISH), digital pathology, and special staining are the technology segments of the tissue diagnostics market. The major players are Abbott Laboratories, Inc. (U.S.), Roche Diagnostics Limited (Switzerland), Danaher Corporation (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Life Technologies (U.S.), Sigma-Aldrich (U.S.), Agilent Technologies (U.S.), Biogenex Laboratories (U.S.), Cell Signaling Technology, Inc. (U.S.), and Bio SB (U.S.).
Upcoming
4 of 4 items
4 reports | Show
Connect With Us
US/CAN : +1-888-502-0539
Tissue Diagnostics